At Week 8, a reversal of genes upregulated in HS lesions and wounded skin was observed after treatment with 30 mg povorcitinib QD (Figure S2a), including downregulation of many interferon (IFN)-stimulated genes, IL-6/STAT3 targets (CCR1, CD14/38, IL1R1, TGFB1, TLR2, and TNFRSF21) [21], genes with innate inflammatory and antiviral functions (e.g., PARP14, ISG20, OAS2, and OASL; Figure 4a), and genes with antimicrobial properties (e.g., TDO2 and DEFB103B; Table S1). Here, CD14 is linked to histiocytic sarcoma.